Becton Dickinson and Co (BDX) Holdings Lessened by CIBC Asset Management Inc

CIBC Asset Management Inc trimmed its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 48,819 shares of the medical instruments supplier’s stock after selling 403 shares during the period. CIBC Asset Management Inc’s holdings in Becton Dickinson and were worth $12,742,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in BDX. Fundsmith Equity Fund L.P. bought a new stake in shares of Becton Dickinson and in the 2nd quarter valued at approximately $894,775,000. Hudson Bay Capital Management LP increased its holdings in shares of Becton Dickinson and by 119.9% in the 2nd quarter. Hudson Bay Capital Management LP now owns 166,094 shares of the medical instruments supplier’s stock valued at $39,789,000 after acquiring an additional 90,564 shares during the last quarter. Kiwi Wealth Investments Limited Partnership bought a new stake in shares of Becton Dickinson and in the 2nd quarter valued at approximately $9,161,000. Parsons Capital Management Inc. RI increased its holdings in shares of Becton Dickinson and by 3.5% in the 2nd quarter. Parsons Capital Management Inc. RI now owns 7,262 shares of the medical instruments supplier’s stock valued at $1,740,000 after acquiring an additional 246 shares during the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Becton Dickinson and by 0.7% in the 2nd quarter. American Century Companies Inc. now owns 1,196,281 shares of the medical instruments supplier’s stock valued at $286,581,000 after acquiring an additional 7,843 shares during the last quarter. 92.60% of the stock is currently owned by institutional investors.

A number of brokerages have recently weighed in on BDX. Citigroup boosted their price target on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Royal Bank of Canada reiterated a “hold” rating and issued a $248.00 price target on shares of Becton Dickinson and in a report on Friday, August 3rd. Barclays began coverage on Becton Dickinson and in a report on Monday, October 15th. They issued an “equal weight” rating and a $278.00 price target for the company. Morgan Stanley boosted their price target on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Finally, Wells Fargo & Co boosted their price target on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $256.14.

Shares of BDX opened at $237.32 on Tuesday. The firm has a market cap of $63.03 billion, a P/E ratio of 25.03, a P/E/G ratio of 1.40 and a beta of 1.19. The company has a quick ratio of 0.81, a current ratio of 1.23 and a debt-to-equity ratio of 0.95. Becton Dickinson and Co has a 12 month low of $209.91 and a 12 month high of $265.87.

WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/11/06/becton-dickinson-and-co-bdx-holdings-lessened-by-cibc-asset-management-inc.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

See Also: Average Daily Trade Volume – ADTV

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply